BRIEF-Geovax Announces Positive Interim Data Review For Phase 2 Clinical Trial Of Covid-19 Vaccine Booster In Patients With Chronic Lymphocytic Leukemia

Reuters11-19

* GEOVAX ANNOUNCES POSITIVE INTERIM DATA REVIEW FOR PHASE 2 CLINICAL TRIAL OF COVID-19 VACCINE BOOSTER IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

* GEOVAX LABS INC - DSMB RECOMMENDS CONTINUATION OF GEO-CM04S1 VACCINE TRIAL

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484940606?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-19 22:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484940606","market":"us","top_or_hot":-1,"title":"BRIEF-Geovax Announces Positive Interim Data Review For Phase 2 Clinical Trial Of Covid-19 Vaccine Booster In Patients With Chronic Lymphocytic Leukemia","media":"Reuters","content":"<html><body><p>Nov 19 (Reuters) - <a href=\"https://laohu8.com/S/GOVX\">GeoVax Labs Inc</a>   :</p><p>   * GEOVAX ANNOUNCES POSITIVE INTERIM DATA REVIEW FOR PHASE 2 CLINICAL TRIAL OF COVID-19 VACCINE BOOSTER IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA</p><p>   * GEOVAX LABS INC - DSMB RECOMMENDS CONTINUATION OF GEO-CM04S1 VACCINE TRIAL</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Geovax Announces Positive Interim Data Review For Phase 2 Clinical Trial Of Covid-19 Vaccine Booster In Patients With Chronic Lymphocytic Leukemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Geovax Announces Positive Interim Data Review For Phase 2 Clinical Trial Of Covid-19 Vaccine Booster In Patients With Chronic Lymphocytic Leukemia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 22:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 19 (Reuters) - GeoVax Labs Inc   :   * GEOVAX ANNOUNCES POSITIVE INTERIM DATA REVIEW FOR PHASE 2 CLINICAL TRIAL OF COVID-19 VACCINE BOOSTER IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA   * GEOVAX...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GOVXW","symbol_name":"GeoVax Labs Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2484940606","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484940606","pubTimestamp":1732026595,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Nov 19  - GeoVax Labs Inc   :   * GEOVAX ANNOUNCES POSITIVE INTERIM DATA REVIEW FOR PHASE 2 CLINICAL TRIAL OF COVID-19 VACCINE BOOSTER IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA   * GEOVAX LABS INC - DSMB RECOMMENDS CONTINUATION OF GEO-CM04S1 VACCINE TRIALSource text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GOVXW":"GeoVax Labs Inc","BK4139":"生物科技","BK4583":"猴痘概念","GOVX":"GeoVax Labs Inc"},"translate_title":"BRIEF-Geovax宣布在慢性淋巴细胞白血病患者中进行Covid-19疫苗加强剂的2期临床试验的积极中期数据审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GOVX":0.6,"GOVXW":0.6},"content_text":"Nov 19 (Reuters) - GeoVax Labs Inc   :   * GEOVAX ANNOUNCES POSITIVE INTERIM DATA REVIEW FOR PHASE 2 CLINICAL TRIAL OF COVID-19 VACCINE BOOSTER IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA   * GEOVAX LABS INC - DSMB RECOMMENDS CONTINUATION OF GEO-CM04S1 VACCINE TRIALSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484940606"}